OncLive TV

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses emerging immunotherapy approaches in bladder cancer.

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma.

Keith T. Flaherty, MD, discusses an update on overall survival in COLUMBUS, a randomized phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Edward B. Garon, MD, MS, discusses the KEYNOTE-001 study, which examined the 5-year long-term overall survival in patients with non–small cell lung cancer treated with pembrolizumab.

Daphne Dumoulin, MD, discusses the NVALT 12 study, a trial examining paclitaxel/carboplatin/bevacizumab inducing peripheral effector CD8 T-cell proliferation that could be prone to treatment in checkpoint inhibitors in patients with non–small cell lung cancer.

Matthew Galsky, MD, discusses the HCRN GU14-182 study, which looked at maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer.

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the goals of androgen deprivation therapy (ADT) in the treatment of patients with prostate cancer.

Sumanta Kumar Pal, MD, an associate clinical professor, Department of Medical Oncology & Therapeutics Research, co-director, Kidney Cancer Program, and medical oncologist at City of Hope, discusses the design of the phase II SWOG 1500 trial (NCT02761057) in locally advanced or metastatic papillary renal cell carcinoma (RCC).

Allen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses frontline therapies in metastatic pancreatic cancer.

Shota Fukuoka, MD, physician, National Cancer Center in Japan, discusses finding the recommended dosage of regorafenib plus nivolumab in patients with advanced gastric cancer or colorectal cancer.

Brian A. Van Tine, MD, PhD, discusses collaboration within the sarcoma field and the importance of clinical trials for advancing treatment.

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital, and assistant professor of medicine at Harvard Medical School, highlights key takeaways from the phase III SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, University of Washington School of Medicine, and attending physician, Hematologic Malignancies, Seattle Cancer Care Alliance, discusses the phase III CLL14 trial in chronic lymphocytic leukemia (CLL).

Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses the rise of molecular testing in metastatic colorectal cancer (mCRC).

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses choosing between immunotherapy agents and TKIs in hepatocellular carcinoma (HCC).

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the potency of gilteritinib (Xospata) in acute myeloid leukemia (AML).

Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses initial findings from the KEYNOTE-365 trial in metastatic castration resistant prostate cancer mCRPC).

Jennifer Carlisle, MD, assistant professor, Winship Cancer Institute of Emory University, discusses how the use of chemoimmunotherapy has become the standard of care in the frontline treatment of patients with squamous non–small cell lung cancer.

Noopur S. Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, highlights the different options available for patients with relapsed multiple myeloma.

Josep M. Llovet, MD, PhD, discusses the REACH and REACH-2 trials, which examined ramucirumab versus placebo in sorafenib-intolerant patients with hepatocellular carcinoma and elevated baseline alpha fetoprotein.

Scott T. Tagawa, MD, discusses the impact of the BRCA2 mutation in patients with prostate cancer who are receiving prostate-specific membrane antigen–targeted radionuclide therapy.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the biggest challenges in the field of bladder cancer.

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses subgroup analyses from the phase III PACIFIC trial in unresectable stage III non–small cell lung cancer (NSCLC).

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses patient eligibility criteria for transplant in multiple myeloma.

Celestia S. Higano, MD, discusses the outcomes of the GETUG-AFU 16 and its impact on current practices for prostate cancer.

Tanios Bekaii-Saab, MD, FACP, discusses the clinical implications of the results of the phase III POLO trial in metastatic pancreatic cancer.

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses safety concerns with venetoclax (Venclexta) in multiple myeloma.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses unmet needs in advanced renal cell carcinoma (RCC).

Lecia V. Sequist, MD, MPH, the Landry Family Associate Professor of Medicine at Harvard Medical School, and director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital, discusses the implications of the phase III IMpower150 trial in advanced nonsquamous non–small cell lung cancer (NSCLC).